Objective-Xanthine oxidase (XO), a major source of superoxide, has been implicated in endothelial dysfunction in atherosclerosis. Mechanisms, however, leading to endothelial XO activation remain poorly defined. We tested the effect of angiotensin II (Ang II) on endothelial XO and its relevance for endothelial dysfunction in patients with coronary disease. Methods and Results-XO protein levels and XO-dependent superoxide production were determined in cultured endothelial cells in response to Ang II. In patients with coronary disease, endothelium-bound XO activity as determined by ESR spectroscopy and endothelium-dependent vasodilation were analyzed before and after 4 weeks of treatment with the AT 1 -receptor blocker losartan, the XO inhibitor allopurinol, or placebo. Ang II substantially increased endothelial XO protein levels and XO-dependent superoxide production in cultured endothelial cells, which was prevented by NAD(P)H-oxidase inhibition. In vivo, endothelium-bound XO activity was reduced by losartan and allopurinol, but not placebo therapy in patients with coronary disease. XO inhibition with oxypurinol improved endothelium-dependent vasodilation before, but not after losartan or allopurinol therapy. Conclusions-These findings suggest a novel mechanism whereby Ang II promotes endothelial oxidant stress, ie, by redox-sensitive XO activation. In patients with coronary disease, losartan therapy reduces endothelium-bound XO activity likely contributing to improved endothelial function. 
I
ncreased vascular production of reactive oxygen species (ROS) is thought to contribute importantly to endothelial dysfunction in experimental atherosclerosis and in patients with coronary disease, in part because of rapid inactivation of endothelial nitric oxide (NO) by superoxide. [1] [2] [3] [4] [5] [6] Furthermore, accumulating evidence suggests that endothelial dysfunction as determined by impaired endothelium-dependent vasodilation is closely associated with cardiovascular events. [7] [8] [9] [10] Therefore, there is a major interest to further understand mechanisms underlying increased vascular production of reactive oxygen species in atherosclerosis.
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Xanthine oxidase (XO) has been identified as a major endothelial source of superoxide 1, 2, 11, 12 that is activated in experimental atherosclerosis. 1,2 Moreover, we and others have recently demonstrated that endothelial XO activity and protein levels are substantially increased in patients with coronary disease or carotid stenosis, 11, 13, 14 and inversely related to endotheliumdependent vasodilation. 11 In addition, serum levels of uric acid, the product of xanthine oxidase, have been suggested as a predictor of cardiovascular disease mortality. 15, 16 The mechanisms, however, leading to increased endothelial XO activation in atherosclerosis remain to be determined.
Angiotensin II (Ang II) represents a major stimulus of endothelial superoxide production in experimental atherosclerosis and likely in patients with coronary disease. [17] [18] [19] We therefore hypothesized that Ang II may impact on endothelial xanthineoxidase protein levels and XO-mediated superoxide production and determined the effect of Ang II on endothelial XO protein levels and XO-mediated superoxide production as assessed by electron spin resonance (ESR) spectroscopy in vitro. Of note, xanthine oxidoreductase is synthesized as xanthine dehydrogenase and needs to be converted to XO to become a source of superoxide. 12 Recent studies have suggested that reactive oxygen species may trigger XO-mediated superoxide production in endothelial cells, and endothelial cells from mice deficient in the NAD(P)H oxidase subunit p47phox had reduced XO activity. 20, 21 We therefore tested the question of whether another source of reactive oxygen species may contribute to endothelial XO activation by Ang II and examined in particular the role of the NAD(P)H oxidase in this process, because Ang II is known to stimulate endothelial NAD(P)H oxidase activity. 22, 23 Furthermore, we hypothesized that Ang II may play an important role for increased endothelial XO activation in patients with coronary disease. To address this question we determined the effect of chronic AT 1 receptor blocker therapy as well chronic XO inhibition by allopurinol on endothelium-bound xanthine-oxidase activity in vivo measured by electron spin resonance spectroscopy in patients with coronary disease. Moreover, we evaluated the effect of acute XO inhibition by oxypurinol on endothelium-dependent vasodilation before and after chronic treatment with losartan or allopurinol in patients with coronary disease.
Methods
An expanded methods section is available online (please see http://atvb.ahajournals.org).
Endothelial Cell Culture
Bovine aortic endothelial cells (BAECs; Clonetics, East Rutherford, NJ) were used between passages 3 and 6 for experiments. BAECs were stimulated with 10 Ϫ7 mol/L of Ang II for 12 hours, a time point that was selected according to the time course of XO protein levels in response to Ang II ( Figure 1A ). NAD(P)H oxidase activation was inhibited by pretreatment (12 hours) with apocynin (500 mol/L) or siRNA transfection for p47phox as described in detail in the online supplement. To exclude that the effect of Ang II on endothelial XO-mediated superoxide production was species specific we performed additional experiments in human aortic endothelial cells (HAECs; PromoCell, Heidelberg, Germany) that were used between passages 3 and 5.
In Vivo Protocol in Patients With CAD
15 patients with angiographically documented stable CAD (left ventricular ejection fraction Ͼ45%) were randomized to 4 weeks of AT 1 -receptor blocker treatment (losartan 50 mg bid; nϭ10) or placebo (nϭ5). Alcohol and caffeine were prohibited within 12 hours of the study. At baseline and after 4 weeks of therapy, flow-dependent, endothelium-mediated vasodilation (FDD) of the radial artery was determined. FDD was measured before and after intraarterial infusion of the XO-inhibitor oxypurinol (600 gϫmin
Ϫ1
; i.a.; 10 minutes; brachial artery) to determine the portion of FDD inhibited by radicals from XO. Furthermore, endothelium-bound XO activity was analyzed before and after 4 weeks of treatment using electron spin resonance spectroscopy. In addition, 9 patients with coronary disease underwent chronic XO inhibition by 4 weeks of treatment with the XO inhibitor allopurinol (300 mg bid), and endothelium-bound XO and endothelium-dependent vasodilation were determined before and after chronic oral XO inhibition.
Patients with an acute coronary syndrome; diabetes mellitus; uncontrolled hypertension; hematologic, renal, or hepatic dysfunction; heparin therapy within the last 48 hours; or patients taking antioxidant vitamin supplements were excluded. Vasoactive medications were withheld, and alcohol and caffeine were prohibited for at least 12 hours before the study. Written informed consent was obtained for all subjects, and the protocol was approved by the local Ethics Committee.
Statistical Analysis
All data are expressed as meanϮSEM. Comparisons of Ͼ2 measurements were done by one-way ANOVA. For the clinical study, both treatment group and time in addition to oxypurinol treatment were considered in the statistical analysis by performing a mixed model analysis using the PROC MIXED statistical procedure (SAS statistical software version 9.1) with "patients" as the random factor and "treatment group", "time", "oxypurinol", and the resulting interactions thereof as fixed effects. This analysis yielded a probability value for the effect "treatment group" ϫ "time" of Pϭ0.0097. One-sided paired t tests or t tests for independent groups were used for further analysis, resulting in probability values as depicted in Figures 4 and 5. The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results

Effect of Ang II on Endothelial XO Protein Levels and XO-Mediated Superoxide Production In Vitro
Ang II administration (10 Ϫ7 mol/L) caused a marked increase of XO protein levels in cultured BAECs ( Figure 1A ). Endothelial superoxide production as determined by electron spin resonance (ESR) spectroscopy (spin trap: CP-H) was increased with a similar time course as compared with endothelial XO protein levels after exposure to Ang II ( Figure 1B) . Importantly, Ang II-induced endothelial superoxide production was markedly reduced by two structurally different XO inhibitors, ie, oxypurinol and tungsten, suggesting that XO contributes critically to Ang II-induced endothelial superoxide formation ( Figure 1C and 1D). In preliminary experiments neither higher (10 Ϫ6 mol/L) nor lower (0.5ϫ10
Ϫ7
) concentrations of Ang II resulted in a more pronounced stimulation of endothelial XO protein levels (data not shown). There was no effect of Ang II on endothelial xanthine dehydrogenase protein levels (data not shown).
Of note, the Ang II-induced increase of both endothelial XO protein levels and superoxide production was blocked by cotreatment with the AT 1 receptor antagonist losartan, but not by the AT 2 -receptor antagonist PD123319 (supplemental Figure I) , suggesting that endothelial XO activation is mediated by the AT 1 -receptor.
Role of the NAD(P)H-Oxidase for Ang II-Induced Endothelial XO Activation
Importantly, both treatment with the NAD(P)H-oxidase inhibitor apocynin or transfection with small interference RNA (siRNA) specific for the NAD(P)H oxidase subunit p47phox prevented Ang II-induced increase of endothelial XO protein levels ( Figure 2 ). Moreover, in endothelial cells treated with the NAD(P)H oxidase inhibitor apocynin or transfected with p47phox specific siRNA there was no increase of superoxide production after stimulation by Ang II (Figure 2) .
To further characterize mechanisms leading to Ang IIinduced increases in endothelial XO protein levels we pretreated endothelial cells with N-acetyl-cysteine, the hydrogen peroxide scavenger catalase, with catalase and superoxide dismutase and with the NO synthase inhibitor L-NAME (supplemental Figure  II) . Catalase and NO-synthase inhibition with L-NAME reduced the increase of endothelial XO protein levels in response to Ang II (supplemental Figure II) . These experiments suggest that both hydrogen peroxide and peroxynitrite are involved in Ang IIinduced increases of endothelial XO protein levels.
To exclude that the effect of Ang II on endothelial XOmediated superoxide production was species specific we performed experiments in HAECs, which have been previously shown to contain XO activity. 24 In these experiments we observed a similar inhibition of Ang II-stimulated superoxide production by the XO inhibitors oxypurinol and tungsten as observed in BAECs (data not shown). To further determine the relevance of Ang II-induced endothelial XO activation in patients with coronary disease we performed a clinical study.
Effect of AT 1 -Receptor Antagonism by Losartan and Chronic XO Inhibition by Allopurinol on Endothelium-Bound Xanthine-Oxidase Activity in Patients With Coronary Disease In Vivo
As shown in Figure 3 , there was a significant release of XO activity from the endothelium into plasma after heparin bolus injection in patients with coronary disease as detected by ESR spectroscopy. Importantly, endothelium-bound XO activity was markedly reduced after 4 weeks of treatment with the AT 1 -receptor antagonist losartan (50 mg bid; Figure 3B ), but not after placebo treatment ( Figure 3A) . Furthermore, 4 weeks of treatment with allopurinol resulted in a significantly reduced endothelium-bound XO activity ( Figure 3C ). Characteristics of patients are shown in the Table. Furthermore, oxpurinol infusion had no effect on endotheliumindependent vasodilation in response to sodium-nitroprusside (19.7Ϯ1.3 versus 20.6Ϯ1.2%; Pϭns; nϭ9), suggesting that oxypurinol infusion specifically improved endotheliumdependent vasodilation in patients with coronary disease. Importantly, after 4 weeks of losartan therapy, but not after placebo treatment, the effect of oxypurinol on endothelium-dependent vasodilation was markedly reduced in patients with CAD, compatible with the notion that chronic AT 1 -receptor blockade improves endothelial function, at least in part, by reducing endothelial XO activation (Figure 4) . To further investigate this concept, 9 patients with coronary disease were treated for 4 weeks with the XO inhibitor allopurinol. Allopurinol therapy resulted in a similar reduction of endothelium-bound XO activity as compared with losartan treatment in patients with coronary disease, as described above, and improved endotheliumdependent vasodilation (Figure 4 ). The analysis of the improvement of FDD after losartan and allopurinol therapy suggested that losartan had a more pronounced effect on FDD as compared with allopurinol treatment (⌬FDD losartan 5.5Ϯ1.1% versus ⌬FDD allopurinol 3.1Ϯ0.5%; PϽ0.05). Although the results of the comparison of the effect of losartan and allopurinol on FDD have to be interpreted with caution, they are compatible with the notion that other mechanisms in addition to XO inhibition do also contribute to improved endothelium-dependent vasodilation after losartan therapy.
Discussion
The major findings of the present study are: (1) Ang II markedly increases endothelial XO protein levels and XO-dependent endothelial superoxide production, suggesting that XO is a major source of superoxide activated by Ang II. (2) Ang II-induced increases of endothelial XO protein levels and superoxide production from XO are prevented by NAD(P)Hoxidase inhibition, suggesting that Ang II activates endothelial XO by a redox-sensitive pathway involving the NADPH oxidase. (3) In vivo, in patients with coronary disease, endothelium-bound XO activity is substantially reduced after 4 weeks of AT 1 -receptor blocker therapy with losartan, but not after placebo treatment as determined by electron spin resonance spectroscopy, suggesting that Ang II is important for endothelial XO activation in human coronary disease. (5) The effect of XO inhibition by oxypurinol on endothelium-dependent vasomotion is substantially reduced after chronic treatment with the AT 1 -receptor blocker losartan in patients with coronary disease, compatible with the notion that Ang II-dependent endothelial XO activation contributes to endothelial dysfunction in coronary disease. Furthermore, chronic XO inhibition by allopurinol inhibits endothelium-bound XO activity to a similar content as compared with losartan treatment and improves endotheliumdependent vasodilation in patients with coronary disease, further supporting the concept that inhibition of endothelial XO contributes to beneficial effects of losartan on endothelial function in patients with coronary disease.
Increased vascular reactive oxygen species production, in particular superoxide, has been suggested as a major cause of endothelial dysfunction in both experimental atherosclerosis and patients with coronary disease. 4, 5 Accumulating evidence suggests that endothelial dysfunction as determined by impaired endothelium-dependent vasodilation is associated with cardiovascular events, likely in part attributable to a loss of vasoprotective properties of endothelial nitric oxide. 5,7-10 Therefore, there has been a major interest to understand mechanisms leading to increased vascular superoxide production and consecutively endothelial dysfunction in atherosclerosis. Experimental studies have identified endothelial XO as a potential major source of endothelial superoxide in atherosclerosis. 1,2 Administration of the XO inhibitor allopurinol or its metabolite oxypurinol reduced vascular superoxide production and improved endothelium-dependent vasodilation in hypercholesterolemic rabbits. 1, 2 In addition, Cardillo et al have described that administration of oxypurinol improved endothelium-dependent vasodilation in patients with hypercholesterolemia. 25 A beneficial effect of XO inhibition on endothelial function has also been observed in patients with other cardiovascular risk factors or heart failure. 26 -28 Furthermore, we and others have recently observed that endothelium-bound XO activity is markedly increased in patients with coronary disease, carotid stenosis, or heart failure and is inversely related to endothelium-dependent vasodilation. 11, 13, 14, 29 In addition, serum levels of uric acid, the product of XO, have been suggested as a predictor of cardiovascular mortality. 15, 16 The mechanisms, however, leading to activation of endothelial XO in atherosclerosis remained largely undefined.
Characteristics of Patients With Coronary Disease
In the present study we provide evidence that Ang II represents a potent stimulus of endothelial XO protein levels and XO-dependent endothelial superoxide production in vitro. Of note, the conversion of xanthine dehydrogenase to XO that is promoting superoxide formation by the enzyme has been shown to be stimulated by reactive oxygen species, in particular peroxynitrite. 30 Moreover, McNally et al have demonstrated increased XO dependent superoxide production in response to oscillatory shear stress and hydrogen peroxide 20, 21 ; however, no increase of XO protein levels was observed in these studies. In contrast, in the present study there was a marked increase of endothelial XO protein levels, but not xanthine dehydrogenase protein levels in response to Ang II. Furthermore, the present study suggests that NAD(P)H oxidase and subsequently hydrogen peroxide and peroxynitrite contribute to increased endothelial XO protein levels in response to Ang II.
Notably, in coronary arteries from patients with coronary disease an increase of XO, but not xanthine dehydrogenase protein levels has recently been observed. 13 The present study suggests, as discussed below, that Ang II is a major stimulus leading to increased vascular XO protein levels in coronary disease. Importantly, we have observed that endothelium-bound XO activity as determined by ESR-spectroscopy is markedly reduced after chronic AT 1 -receptor blocker therapy with losartan in patients with coronary disease, but not after placebo treatment. This could represent a novel mechanism whereby AT 1 -receptor blocker therapy improves endothelial function in patients with coronary disease. To further evaluate this concept we have determined the effect of the XO inhibitor oxypurinol on endothelium-dependent vasodilation before and after chronic AT 1 -receptor blocker therapy in patients with coronary disease. These studies revealed a marked reduction of the effect of oxypurinol on endothelium-dependent vasodilation in patients with CAD after AT 1 -receptor blockade, compatible with the concept that Ang II-dependent XO activation contributes to endothelial dysfunction in coronary disease.
We cannot, however, exclude the possibility that improved endothelium-dependent vasodilation after losartan therapy may have contributed to a reduced effect of oxypurinol on endothelium-dependent vasodilation after losartan therapy in patients with coronary disease. To further address this issue we have studied the effect of 4 weeks of allopurinol therapy on endothelium-bound XO activity and endothelial function in patients with coronary disease. Allopurinol treatment resulted in a similar reduction of endothelium-bound XO activity as compared with losartan treatment, and improved endothelium-dependent vasodilation, further suggesting that reduced endothelial XO activation after losartan therapy contributes to beneficial effects on endothelium-dependent vasodilation. Of note, other mechanisms in addition to XO inhibition are likely to contribute to beneficial effects of losartan therapy on endothelial function as well, because the effect of losartan therapy on endothelium-dependent vasodilation appeared to be more pronounced as compared with allopurinol treatment, despite a similar reduction of endothelium-bound XO activity. These include prevention of NAD(P)H oxidase dependent superoxide production, increased scavenging of superoxide by extracellular superoxide dismutase, and increased activation of the AT 2 receptor after blockade of the AT 1 receptor. 17, 31, 32 
Study Limitations
The number of patients in the placebo group of the clinical part of the present study represents a potential limitation. Because the novel ESC guidelines do recommend ACE inhibitor therapy for patients with coronary disease, our ethics committee did not permit the study of further patients on placebo treatment. However, in this regard, it must be emphasized that the measurements of the endothelial release of XO were performed by ESR spectroscopy at multiple time points after heparin bolus injection to have a particular high accuracy of these analyses.
In addition, the present study was not powered to assess the impact of losartan treatment on uric acid serum levels, the product of XO. However, a recent analysis of the LIFE study has shown an attenuation of the increase of serum uric acid levels over 4.8 years of losartan treatment, which was not observed with atenolol therapy, and this has been suggested to explain up to 29% of the treatment effect on the primary composite end point. 33 It is therefore tempting to speculate that inhibition of endothelium-bound XO may contribute to prevention of an increase of uric acid serum levels over time in addition to an uricosuric effect of losartan.
In summary, the present study describes a novel mechanism of endothelial oxidant stress in response to Ang II, ie, redoxsensitive activation of endothelial XO ( Figure 5 ). We further provide evidence that Ang II-dependent stimulation of endothelial XO activity plays a major role for increased endotheliumbound XO activity in patients with coronary disease, because endothelium-bound XO activity was markedly reduced after chronic AT 1 -receptor blockade as determined by ESR spectroscopy. In addition, our findings are compatible with the notion that Ang II-dependent XO activation contributes to endothelial dysfunction in patients with coronary disease.
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